R v Cambridge Health Authority

Factual and Procedural Background

This opinion concerns an application for leave to appeal, and if granted, an appeal against a decision of the High Court Judge (Laws J) regarding the refusal of a Health Authority to fund further medical treatment for a minor child suffering from a serious illness. The court made a direction under section 39 of the Children and Young Persons Act 1933 to protect the identity of the child involved, who is critically ill and unaware of her condition.

The child, aged 10, was initially diagnosed in 1990 with non-Hodgkins lymphoma and acute lymphoblastic leukaemia and underwent chemotherapy. After initial success, she relapsed in 1993 with acute myeloid leukaemia and received further chemotherapy and total body irradiation, followed by a bone marrow transplant in 1994. A further relapse in January of the year of the proceedings prompted the request for additional treatment involving a third chemotherapy course and a possible second bone marrow transplant.

The child's family, particularly her father, sought funding from the respondent Health Authority for this treatment. Medical opinions within the United Kingdom generally indicated a very low chance of success and considered the proposed treatment experimental. Some doctors in the United States offered a more optimistic prognosis but at prohibitive cost. The Health Authority ultimately declined to fund the treatment, leading to judicial review proceedings.

The High Court quashed the Health Authority’s decision, prompting the present appeal before the Court of Appeal.

Legal Issues Presented

1. Whether the Health Authority lawfully and reasonably exercised its discretion in refusing to fund further treatment for the child.
2. Whether the Health Authority failed to take into account relevant considerations, including the wishes of the patient and her family.
3. Whether the description of the treatment as "experimental" was a fair characterization affecting the decision’s reasonableness.
4. Whether the Health Authority properly considered the allocation and limitations of its financial resources in making its decision.
5. Whether the Health Authority erred in treating the treatment cost as a single stage rather than a two-stage process.

Arguments of the Parties

Appellant's Arguments

• The Health Authority failed to consider the wishes of the patient and her family as a vital factor in the decision-making process.
• The treatment was unfairly described as "experimental," despite reputable medical opinions estimating a 10-20% chance of success and willingness by some doctors to undertake the treatment.
• The Health Authority’s consideration of resource allocation was inadequate, lacking explanation of priorities and the impact on other patients.
• The Health Authority erred in treating the treatment cost as a single stage expenditure rather than recognizing the two-stage nature of the treatment.

Respondent's Arguments

• The decision maker was fully aware of the family’s wishes and the pressure exerted but made a careful and agonizing decision based on clinical judgment.
• The treatment was properly described as experimental since it lacked a well-tried track record and was at the frontier of medical science.
• Resource allocation decisions are necessarily difficult and courts should not expect Health Authorities to provide detailed financial accounts or demonstrate direct impact on other patients.
• The cost must be considered as a whole since the second stage would follow if the first was successful, making it reasonable to treat it as a single decision.

Table of Precedents Cited

No precedents were cited in the provided opinion.

Court's Reasoning and Analysis

The Court of Appeal emphasized the paramount importance of human life but underscored its limited role as a legal arbiter rather than a medical or resource allocation decision-maker. It rejected the High Court’s criticisms on several grounds:

• The court found that the Health Authority’s decision maker was sufficiently aware of the family’s wishes, despite the absence of an explicit statement to that effect in the decision documentation.
• The description of the treatment as "experimental" was justified given the low chances of success and the novel nature of the proposed treatment.
• While sympathetic to the appellant’s position, the court recognized the reality of limited Health Authority resources and declined to require detailed financial justifications or prioritizations from the Authority.
• The decision to treat the treatment cost as a single-stage consideration was reasonable because the second phase would only proceed if the first was successful, and the Authority was entitled to consider the overall financial and clinical implications.

The court concluded that the Health Authority’s refusal to fund the treatment was lawful and reasonable, and that the High Court had erred in quashing the decision.

Holding and Implications

APPEAL ALLOWED

The Court of Appeal allowed the appeal, reinstating the Health Authority’s decision not to fund further treatment. The court held that the Authority’s decision was within its legal powers and was not unreasonable. The direct effect is that the Health Authority’s refusal stands, and no additional funding is mandated. No new legal precedent was established, and the court reaffirmed the limited judicial role in medical resource allocation decisions.